Efficacy of Prazosin Versus Placebo Associated With Peg-interferon Alpha 2b and Ribavirin in Chronic Hepatitis C With Genotype 1 or 4 and Severe Fibrosis

Study acronym: PRAZOR
StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Active, Not Recruiting to Completedv6 Show 5 more changesShow less
    • Primary and study completion dates: Dec 2008
    • Interventions: Peg-interferon alpha 2b (drug) (Drug), Prazosin (drug) (Drug), Ribavirin (drug) (Drug) to Peg-interferon alpha 2b + Ribavirin(drug) (Drug), Prazosin (drug) (Drug)
    • Secondary endpoints: details revised at 3 of 3 entries
    • Study arms: 0 to 2
    • Collaborators expanded, about 1 word
  2. Re-verified, no change to tracked fieldsv5
  3. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised
    v4
  4. Re-verified, no change to tracked fieldsv3
  5. Study Identification, Study Statusv2
  6. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Viral hepatitis C prognosis is related to the presence of a fibrosis and to the risk of developing cirrhosis or hepatic cancer. The study will evaluate the efficacy of prazosin to make hepatic fibrosis regress, in patients with chronic hepatitis C and severe fibrosis.
Trial Details
NCT Number NCT00148837
Lead Sponsor French National Agency for Research on AIDS and Viral Hepatitis
Collaborators: Pfizer
Conditions
(from sponsor)		 Hepatitis C, Chronic, Fibrosis
Related terms Fibrosis, Hepatitis C, Chronic
Enrollment 112 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov